Has Neelima Vidula, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,703 in general payments to Neelima Vidula, MD across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neelima Vidula, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neelima Vidula, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neelima Vidula, MD

Internal Medicine · Boston, MANPI 1669793014

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $16,588 of the $17,703 with a category attached, or 93.7%. 8 manufacturers reported payments, led by Novartis at 25.7% of the total. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,703in general payments, 2019–2025

Across 21 payments — averaging $843.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$5K
Gilead$3K
Stemline Therapeutics Inc.$3K
Pfizer$3K
Tersera Therapeutics LLC$2K
Daiichi Sankyo Inc.$1K
plus $485 from 2 others

$1,418,761in research payments, 2019–2025

Across 89 payments — averaging $15,941 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$1.1M
Novartis$260K
AstraZeneca$48K
Stemline Therapeutics Inc.$20K
Radius Health, Inc.$9K
E.r. Squibb & Sons, L.L.C.$1K

What the payments were for

Consulting fees$16,58894%
Grants$3502%
Food & beverage$7654%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	2	$4,556
Gilead	2	$3,207
Stemline Therapeutics Inc.	8	$3,113
Pfizer	2	$2,874
Tersera Therapeutics LLC	4	$2,238
Daiichi Sankyo Inc.	1	$1,230
AstraZeneca	1	$350
Astrazeneca UK Limited	1	$135

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

KISQALI$4,556
Trodelvy$3,170
Orserdu$2,959
IBRANCE$2,800
ZOLADEX$2,213
DATROWAY$1,230

How this compares

$17,703 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$79,774

Medicare patients

215

Services billed

765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Letrozole	38	$1,019

Paid to pharmacies, not to this prescriber.

Other internal medicine in Boston

David SchenkeinBoston$5M
John FallonBoston$1.8M
Michael MendelsohnBoston$1.6M
Gaurav SingalBoston$798K
Asit ParikhBoston$486K
Noopur RajeBoston$481K
Daniel KuritzkesBoston$443K
Xiuning leBoston$364K
Nancy GaglianoBoston$358K
Fatima StanfordBoston$285K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →